Among histone‐modifying drugs, EZH2 inhibitors like GSK126 enhance natural killer (NK) cell activity in HCC, while dual inhibitors like CM272 (targeting DNMT1 and G9a) improve tumor suppressor gene activation while reducing tumor proliferation.89, 114. This evidence concerns the gene EZH2 and hepatocellular carcinoma.